Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

(2021) David A. Sallman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

(2021) Paola Menichini et al.   Cells

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Specific RITA modification produces hyperselective cytotoxicity while maintaining in vivo antitumor efficacy

(2019) Brian D Peyser et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer

(2019) Park et al.   Cancers

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

(2019) Naoise C. Synnott et al.   BREAST CANCER RESEARCH AND TREATMENT

Restoration of conformation of mutant p53

(2018) J A Green et al.   ANNALS OF ONCOLOGY

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

(2018) Michael J. Duffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic strategies

(2018) Raman Preet Kaur et al.   CURRENT PHARMACEUTICAL DESIGN

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

(2018) Sara Ibrahim Omar et al.   Oncotarget

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

(2017) Anne Perdrix et al.   Cancers

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo

(2016) Kowthar Y. Salim et al.   Oncotarget

The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression

(2016) Jiandong Chen   Cold Spring Harbor Perspectives in Medicine

Pharmacological reactivation of p53 as a strategy to treat cancer

(2015) J. Zawacka-Pankau et al.   JOURNAL OF INTERNAL MEDICINE

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38

(2014) A Weilbacher et al.   Cell Death & Disease

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

(2013) Christopher D. Wassman et al.   Nature Communications

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Epithelial-Mesenchymal Transition

(2009) Michael W. Klymkowsky et al.   AMERICAN JOURNAL OF PATHOLOGY

Tumor Suppressive Functions of p53

(2009) J. T. Zilfou et al.   Cold Spring Harbor Perspectives in Biology

Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague–Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study

(2008) Indira Benakanakere et al.   ENDOCRINE-RELATED CANCER

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

(2008) J. E. Kravchenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA